drugset / Trial / NCT01178138
Monoamine Antagonist Therapies for Methamphetamine Abuse Prazosin
Phase 2
Completed
24 enrolled
University of Arkansas
National Institute on Drug Abuse (NIDA) · collab
NaSingle-groupTriple-blindHealth-services research
Summary
This protocol will test the safety, effectiveness and the metabolism and action of prazosin as a potential therapy for methamphetamine abuse. This will be accomplished by performing a series of human laboratory studies. In each of these studies, the safety and effectiveness of the test medication (prazosin) in the treatment of methamphetamine effects will be determined. The study hypothesis is that prazosin will block the methamphetamine receptor function, reducing the reinforcing effects of central nervous system effects in humans.
Timeline
- Start
- 2009-12
- Primary completion
- 2013-06
- Completion
- 2013-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Prazosin | Unknown | 1 mg | Oral |
| Subject | Prazosin | Unknown | 2 mg | Oral |